Tango Therapeutics Inc (TNGX)

May 01, 2025

There is no way Tango Therapeutics Inc (TNGX) can keep these numbers up - Sete News

May 01, 2025

May 01, 2025

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewswire

May 01, 2025

Apr 30, 2025

Is Tango Therapeutics Inc (TNGX) worth investing in despite its undervalued state? - uspostnews.com

Apr 30, 2025

Apr 30, 2025

Tango Therapeutics Inc (TNGX) Stock: A Year of Highs and Lows - investchronicle.com

Apr 30, 2025

Apr 29, 2025

Insider’s View: Deciphering Tango Therapeutics Inc (TNGX)’s Financial Health Through Ratios - DWinneX

Apr 29, 2025

Apr 28, 2025

Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace

Apr 28, 2025

Apr 27, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Geode Capital Management LLC - Defense World

Apr 27, 2025

Apr 26, 2025

Now Is The Time To Build A Position In Tango Therapeutics Inc (NASDAQ:TNGX) - Marketing Sentinel

Apr 26, 2025

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025

Apr 24, 2025

Gaining Ground: Tango Therapeutics Inc (TNGX) Closes Lower at 2.35, Down -0.42 - DWinneX

Apr 24, 2025

Apr 24, 2025

What is the investor’s view on Tango Therapeutics Inc (TNGX)? - uspostnews.com

Apr 24, 2025

Apr 18, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Franklin Resources Inc. - Defense World

Apr 18, 2025

Apr 17, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $12.33 Average PT from Analysts - Defense World

Apr 17, 2025

Apr 17, 2025

Equities Analysts Offer Predictions for TNGX Q1 Earnings - Defense World

Apr 17, 2025

Apr 16, 2025

Tango Bypasses IPO Route With SPAC Merger - insights.citeline.com

Apr 16, 2025

Apr 16, 2025

What is HC Wainwright’s Estimate for TNGX Q1 Earnings? - Defense World

Apr 16, 2025

Apr 15, 2025

Tango Therapeutics’ (TNGX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Apr 15, 2025

Apr 14, 2025

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - MSN

Apr 14, 2025

Apr 14, 2025

Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright - Investing.com Canada

Apr 14, 2025

Apr 14, 2025

Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright By Investing.com - Investing.com South Africa

Apr 14, 2025

Apr 14, 2025

Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding - simplywall.st

Apr 14, 2025

Apr 14, 2025

American Century Companies Inc. Purchases 12,162 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Apr 14, 2025

Apr 09, 2025

Barbara Weber, M.D., Elected to ITM Supervisory Board - Yahoo

Apr 09, 2025

Apr 09, 2025

Reviewing Biomea Fusion (NASDAQ:BMEA) and Tango Therapeutics (NASDAQ:TNGX) - Defense World

Apr 09, 2025

Apr 07, 2025

Tango Therapeutics cuts nearly one-fifth of staff - BioPharma Dive

Apr 07, 2025

Apr 03, 2025

TNGX’s Wild Ride: Down -55.66% – What’s Next for TNGX? - investchronicle.com

Apr 03, 2025

Apr 02, 2025

How Will Tango Therapeutics Inc (NASDAQ: TNGX) Perform In Months To Come? - Marketing Sentinel

Apr 02, 2025

Mar 31, 2025

Swiss National Bank Raises Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 31, 2025

Mar 30, 2025

Charles Schwab Investment Management Inc. Acquires 26,192 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 30, 2025

Mar 29, 2025

Bank of New York Mellon Corp Sells 8,715 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 29, 2025

Mar 25, 2025

Tango Therapeutics to Highlight Preclinical Data on - GlobeNewswire

Mar 25, 2025

Mar 25, 2025

Breakthrough: Novel Brain-Penetrant Cancer Drugs Target Previously Untreatable Tumors - Stock Titan

Mar 25, 2025

Mar 24, 2025

Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa

Mar 24, 2025

Mar 24, 2025

Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials - Investing.com

Mar 24, 2025

Mar 21, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest Up 18.5% in February - Defense World

Mar 21, 2025

Mar 13, 2025

Tango Therapeutics executive sells shares worth $43,865 - MSN

Mar 13, 2025

Mar 13, 2025

Cantor Fitzgerald Issues Negative Forecast for TNGX Earnings - Defense World

Mar 13, 2025

Mar 10, 2025

Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday - Defense World

Mar 10, 2025

Mar 07, 2025

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - MSN

Mar 07, 2025

Mar 06, 2025

Mesothelioma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 06, 2025

Feb 28, 2025

Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat

Feb 28, 2025

Feb 28, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough - Simply Wall St

Feb 28, 2025

Feb 28, 2025

Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint - Yahoo Finance UK

Feb 28, 2025

Feb 28, 2025

Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks

Feb 28, 2025

Feb 27, 2025

Tango Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada

Feb 27, 2025

Feb 27, 2025

Tango Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 27, 2025

Feb 27, 2025

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times

Feb 27, 2025

Feb 27, 2025

Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 27, 2025

Feb 27, 2025

Can Tango's Cancer Breakthroughs in Pancreatic and Lung Cancer Outweigh Its Growing Losses? - StockTitan

Feb 27, 2025

Feb 23, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Feb 23, 2025

Feb 23, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter

Feb 23, 2025